Journal of
AIDS and HIV Research

  • Abbreviation: J. AIDS HIV Res.
  • Language: English
  • ISSN: 2141-2359
  • DOI: 10.5897/JAHR
  • Start Year: 2009
  • Published Articles: 283

Full Length Research Paper

Assessment of renal dysfunction and associated factors among patients on Tenofovir based antiretroviral treatment at Gondar University Hospital, North West Ethiopia: Retrospective institution based cross sectional study

Endris Ahmed
  • Endris Ahmed
  • Department of Internal Medicine, College of medicine and health sciences, University of Gondar, P. O. Box 196, Gondar, Ethiopia.
  • Google Scholar
Ermias Diro
  • Ermias Diro
  • Department of Internal Medicine, College of medicine and health sciences, University of Gondar, P. O. Box 196, Gondar, Ethiopia.
  • Google Scholar
Workagegnehu Hailu
  • Workagegnehu Hailu
  • Department of Internal Medicine, College of medicine and health sciences, University of Gondar, P. O. Box 196, Gondar, Ethiopia.
  • Google Scholar
Oumer Abdu Muhie
  • Oumer Abdu Muhie
  • Department of Internal Medicine, College of medicine and health sciences, University of Gondar, P. O. Box 196, Gondar, Ethiopia.
  • Google Scholar


  •  Received: 15 July 2019
  •  Accepted: 18 May 2020
  •  Published: 31 October 2020

References

Adolescents PoAGfAa (2008). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Services DoHaH, Washington, DC.

 

Adolescents PoAGfAa (2011). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (DHHS) 1-166.

 

Ansari PP, Ansari N (2008). Acute renal failure in an AIDS patient on tenofovir: a case report. Journal of Medical Case Reports 2(1):94.
Crossref

 

compared with nucleoside reverse-transcriptase inhibitor treatment. Clinical Infectious Diseases 40(8):1194-8.

 

Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clinical Infectious Diseases 51(5):496-505.
Crossref

 

FBaGS (2005). Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19(1):93-9.
Crossref

 

Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy, 12(8):1165.

 

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. Jama 292(2):191-201.
Crossref

 

Gallant JE, Parish MA, Keruly JC, Moore RD (2005). Changes in renal function associated with tenofovir disoproxil fumarate treatment,

 

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, California Collaborative Treatment Group 578 (2008). Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. The Journal of infectious diseases 197(1):102-108.
Crossref

 

HAPCO/MOH F (2008). Guideline for the management of opportunistic infections and antiretroviral treatment in adolescent and adults in Ethiopia.

 

Hassane I, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, Launay-Vacher V, Deray G (2004). Renal safety of tenofovir in HIV treatment-experianced patients AIDS 18(7):1074-6.
Crossref

 

HIV medicine (2007). 

View

 

Jim Younga, Schäfer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC (2012). Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 26(5):567-75.
Crossref

 

Joel EG, Moore RD (2005). Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS (Londan ,England) 23(15):1971-5
Crossref

 

Joel EG, Moore RD (2009). Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS (Londan, England) 23(15):1971.
Crossref

 

Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, Gazzard B (2004). Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. JAIDS Journal of Acquired Immune Deficiency Syndromes 37(4):1489-95.
Crossref

 

KDIGO (2012). Clinical practice guideline for the evaluation and management of chronic kidney disease 3(1).

 

Ketan Kk, Patel AK, Ranjan RR, Patel AR, Patel JK (2010). Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian Journal sexual transmited diseasse 31(1):30.
Crossref

 

Laprise C, Baril JG, Dufresne S, Trottier H (2013). Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clinical infectious diseases 56(4):567-78.
Crossref

 

Michael H, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry Jr C, Klein D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients (2010). Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 53(1):62-69.
Crossref

 

Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren, J.D. and EuroSIDA Study Group (2010).Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24(11):1667-78.
Crossref

 

Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S (2007). The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21(10):1273-1281.
Crossref

 

Paul OD, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella Jr FJ (2011). Low incidence of renal impairment observed in tenofovir-treated patients. Journal of antimicrobial chemotherapy 66(5):1120-1126.
Crossref

 

Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Céron D. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. Journal of Acquired Immune Deficiency Syndromes 35(3):269-73.
Crossref

 

Post FA (2010). Biomarkers of impaired renal function. Current Opinion in HIV and AIDS 5(6):524-30.
Crossref

 

Sasisopin K, Chaisiri K, Kasettratat N, Visuttimak P, Bowonwatanuwong C (2011). Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-limited setting. Journal of the International Association of Physicians in AIDS Care (JIAPAC) 10(5):297-302.
Crossref

 

Scherzer R, Estrella M, Yongmei LI, Deeks SG, Grunfeld C, Shlipak MG (2012). Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26(7):867-75.
Crossref

 

UNAIDS (2013). HIV and AIDS Estimate RSTESA. 

View

 

Wandeler G, Lloyd M, Musonda P, Mwango A, Vinikoor MJ, Davies MA., Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, (2014). Effect of Baseline Renal Function on Tenofovir-Containing Antiretroviral Therapy Outcomes in Zambia. Clinical Infectious Diseases 58(10):1473-1480.
Crossref

 

WHO (2007). AIDS epidemic update. Geneva. 

View

 

WHO (2010). Antiretroviral therapy for HIV infection in adults and adolescents. recommendations for a public health approach-2010 revision. World Health Organization.

 

Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G (2006). Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clinical Infectious Diseases 42(2):283-90.
Crossref